目次

TABLE OF CONTENTS

1 INTRODUCTION
1.1 OBJECTIVES OF THE STUDY
1.2 MARKET DEFINITION
1.2.1 INCLUSIONS & EXCLUSIONS
1.2.2 MARKETS COVERED
1.2.3 YEARS CONSIDERED FOR THE STUDY
1.3 CURRENCY
1.4 LIMITATIONS
1.5 STAKEHOLDERS
1.6 SUMMARY OF CHANGES
1.6.1 RECESSION IMPACT

2 RESEARCH METHODOLOGY
2.1 RESEARCH APPROACH
2.1.1 SECONDARY SOURCES
2.1.1.1 KEY DATA FROM SECONDARY SOURCES
2.1.2 PRIMARY SOURCES
2.1.2.1 KEY DATA FROM PRIMARY SOURCES
2.1.2.2 BREAKDOWN OF PRIMARIES
2.1.2.3 KEY INDUSTRY INSIGHTS
2.2 MARKET SIZE ESTIMATION
2.2.1 LEUKAPHERESIS MARKET
2.2.1 LEUKOPAKS MARKET
2.3 MARKET BREAKDOWN AND DATA TRIANGULATION
2.4 MARKET SHARE ESTIMATION
2.5 ASSUMPTIONS FOR THE STUDY
2.6 RISK ASSESSMENT
2.7 LIMITATIONS
2.8 RECESSION IMPACT ANALYSIS

3 EXECUTIVE SUMMARY

4 PREMIUM INSIGHTS
4.1 LEUKAPHERESIS PRODUCTS MARKET: OVERVIEW
4.2 NORTH AMERICA: LEUKAPHERESIS PRODUCTS MARKET, BY TYPE AND COUNTRY
4.3 LEUKAPHERESIS PRODUCTS MARKET: GEOGRAPHIC MIX
4.4 LEUKAPHERESIS PRODUCTS MARKET: REGIONAL MIX
4.5 LEUKOPAKS MARKET: OVERVIEW
4.6 NORTH AMERICA: LEUKOPAKS MARKET, BY PRODUCT AND COUNTRY
4.7 LEUKOPAKS MARKET: GEOGRAPHIC MIX
4.8 LEUKOPAKS MARKET: REGIONAL MIX

5 MARKET OVERVIEW
5.1 INTRODUCTION
5.2 MARKET DYNAMICS
5.2.1 DRIVERS
5.2.2 RESTRAINTS
5.2.3 OPPORTUNITIES
5.2.4 CHALLENGES
5.3 INDUSTRY INSIGHTS
5.4 INDUSTRY TRENDS
5.5 VALUE CHAIN ANALYSIS
5.6 TECHNOLOGY ANALYSIS
5.7 PORTER'S FIVE FORCE ANALYSIS
5.8 REGULATORY LANDSCAPE
5.8.1 REGULATORY ANALYSIS (LEUKAPHERESIS MARKET)
5.8.2 REGULATORY ANALYSIS (LEUKOPAKS MARKET)
5.8.3 REGULATORY BODIES, GOVERNMENT AGENCIES AND OTHER ORGANIZATION
5.9 PATENT ANALYSIS (LEUKAPHERESIS MARKET)
5.10 PATENT ANALYSIS (LEUKOPAKS MARKET)
5.11 PRICING ANALYSIS (LEUKOPAKS MARKET)
5.11.1 AVERAGE SELLING PRICE TREND OF KEY PLAYERS, BY TYPE
5.11.2 AVERAGE SELLING PRICE TREND OF LEUKOPAKS, BY REGION
5.12 LEUKAPHERESIS MARKET VENDORS: MAJOR CUSTOMERS
5.13 KEY CONFERENCES & EVENTS DURING 2023-2024
5.14 KEY STAKEHOLDERS & BUYING CRITERIA
5.14.1 KEY STAKEHOLDERS & BUYING PROCESS
5.14.2 BUYING CRITERIA
5.15 ECOSYSTEM ANALYSIS
5.16 CASE STUDY ANALYSIS
5.17 HS CODES: CENTRIFUGAL DEVICES AND MEMBRANE SEPARATORS
5.18 ADJACENT MARKET ANALYSIS

6 LEUKAPHERESIS PRODUCTS MARKET, BY TYPE, 2021-2028 (USD MILLION)
6.1 INTRODUCTION
6.2 LEUKAPHERESIS DISPOSABLES
6.3 LEUKAPHERESIS DEVICES
6.3.1 CENTRIFUGAL DEVICES
6.3.2 MEMBRANE SEPARATORS

7 LEUKAPHERESIS PRODUCTS MARKET, BY APPLICATION, 2021-2028 (USD MILLION)
7.1 INTRODUCTION
7.2 RESEARCH APPLICATIONS
7.3 THERAPEUTIC APPLICATIONS

8 LEUKAPHERESIS PRODUCTS MARKET, BY END USER, 2021-2028 (USD MILLION)
8.1 INTRODUCTION
8.2 BLOOD COMPONENT PROVIDERS & BLOOD CENTERS
8.3 ACADEMIC & RESEARCH INSTITUTES
8.4 PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES
8.5 HOSPITALS & TRANSFUSION CENTERS

9 LEUKOPAKS MARKET, BY TYPE, 2021-2028 (USD MILLION)
9.1 INTRODUCTION
9.2 MOBILIZED LEUKOPAKS
9.3 NON-MOBILIZED LEUKOPAKS
9.4 DISEASED LEUKOPAKS
9.5 ISOLATED PBMCS

10 LEUKOPAKS MARKET, BY INDICATION, 2021-2028 (USD MILLION)
10.1 INTRODUCTION
10.2 ACUTE LYMPHOCYTIC LEUKEMIA
10.3 MULTIPLE MYELOMA
10.4 NON-HODGKIN’S LYMPHOMA
10.5 CHRONIC LYMPHOCYTIC LEUKEMIA
10.6 PANCREATIC CANCER
10.7 HEPATOCELLULAR CARCINOMA
10.8 OTHER INDICATIONS

11 LEUKOPAKS MARKET, BY END USER, 2021-2028 (USD MILLION)
11.1 INTRODUCTION
11.2 ACADEMIC & RESEARCH INSTITUTES
11.3 PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES
11.4 CONTRACT RESEARCH ORGANIZATIONS

12 LEUKAPHERESIS MARKET, BY REGION, 2021-2028 (USD MILLION)
12.1 INTRODUCTION
12.2 NORTH AMERICA
12.2.1 RECESSION IMPACT
12.2.2 US
12.2.3 CANADA
12.3 EUROPE
12.3.1 RECESSION IMPACT
12.3.3 GERMANY
12.3.4 UK
12.3.5 FRANCE
12.3.6 SPAIN
12.3.7 ITALY
12.3.8 REST OF EUROPE
12.4 ASIA PACIFIC
12.4.1 RECESSION IMPACT
12.4.2 JAPAN
12.4.3 CHINA
12.4.4 INDIA
12.4.5 AUSTRALIA
12.4.6 SOUTH KOREA
12.4.7 REST OF ASIA PACIFIC
12.5 LATIN AMERICA
12.5.1 RECESSION IMPACT
12.6 MIDDLE EAST & AFRICA
12.6.1 RECESSION IMPACT

13 COMPETITIVE LANDSCAPE
13.1 OVERVIEW
13.2 KEY PLAYER STRATEGIES/RIGHT TO WIN
13.3 REVENUE SHARE ANALYSIS OF KEY PLAYERS (2022)
13.4 PRODUCT FOOTPRINT ANALYSIS OF TOP PLAYERS IN LEUKAPHERESIS PRODUCTS AND LEUKOPAKS MARKETS
13.5 LEUKAPHERESIS MARKET SHARE ANALYSIS (2022)
13.6 LEUKOPAKS MARKET SHARE ANALYSIS (2022)
13.7 COMPANY EVALUATION MATRIX (2022) (LEUKAPHERESIS PRODUCTS MARKET)
13.7.1 STARS
13.7.2 EMERGING LEADERS
13.7.3 PERVASIVE PLAYERS
13.7.5 PARTICIPANTS
13.7.6 COMPANY FOOTPRINT
13.8 START-UPS/SME EVALUATION MATRIX (2022) (LEUKAPHERESIS PRODUCTS MARKET)
13.8.1 PROGRESSIVE COMPANIES
13.8.2 RESPONSIVE COMPANIES
13.8.3 DYNAMIC COMPANIES
13.8.4 STARTING BLOCKS
13.8.5 COMPETITIVE BENCHMARKING
13.9 COMPANY EVALUATION MATRIX (2022) (LEUKOPAKS MARKET)
13.9.1 STARS
13.9.2 EMERGING LEADERS
13.9.3 PERVASIVE PLAYERS
13.9.5 PARTICIPANTS
13.9.6 COMPETITIVE BENCHMARKING
13.1 COMPETITIVE SITUATION AND TRENDS
13.10.1 PRODUCT LAUNCHES
13.10.3 DEALS
13.10.4 EXPANSIONS

14 COMPANY PROFILES
14.1 KEY PLAYERS
14.1.1 ASAHI KASEI MEDICAL CO. LTD. (JAPAN)
14.1.2 FRESENIUS SE & CO. KGAA (GERMANY)
14.1.3 HAEMONETICS CORPORATION (US)
14.1.4 TERUMO BCT, INC. (US)
14.1.5 MACOPHARMA SA (FRANCE)
14.1.6 MILTENYI BIOTEC (GERMANY)
14.1.7 GUANGZHOU DAJI MEDICAL SCIENCE AND TECHNOLOGY CO. LTD. (CHINA)
14.1.8 MEDICA S.P.A (ITALY)
14.1.9 PURIBLOOD MEDICAL CO. LTD. (TAIWAN)
14.2 OTHER PLAYERS (LEUKAPHERESIS MARKET)
14.2.1 BEIJING ZKSK TECHNOLOGY CO. LTD. (CHINA)
14.2.2 MALLINCKRODT PHARMACEUTICALS
14.2.3 NIKKISO CO., LTD. (JAPAN)
14.2.4 PALL CORPORATION
14.3 KEY PLAYERS (LEUKOPAKS MARKET)
14.3.1 ALLCELLS, LLC (US)
14.3.2 STEMEXPRESS, LLC. (US)
14.3.3 CHARLES RIVER LABORATORIES (US)
14.3.4 LONZA GROUP AG (SWITZERLAND)
14.3.5 CALTAG MEDSYSTEMS LIMITED (UK)
14.3.6 ZENBIO (US)
14.4 OTHER PLAYERS (LEUKOPAKS MARKET)
14.4.1 PRECISION FOR MEDICINE (US)
14.4.2 BIOIVT (US)
14.4.3 INTELLIGENT TISSUE GROUP (US)
14.4.4 TRINA BIOREACTIVES AG (SWITZERLAND)
14.4.5 ACCEGEN
14.4.6 FIRST CHOICE BIO LLC

15 APPENDIX
15.1 INSIGHTS OF INDUSTRY EXPERTS
15.2 DISCUSSION GUIDE
15.3 KNOWLEDGE STORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL
15.4 AVAILABLE CUSTOMIZATION
15.5 RELATED REPORTS
15.6 AUTHOR DETAILS